Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02304419 · ClinicalTrials.gov registry record · Phase 1
A Study of Galunisertib on the Immune System in Participants With Cancer
A Phase 1 study of Neoplasm, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT02304419: Completed Phase 1 study of Neoplasm, sponsored by Eli Lilly and Company.
NCT02304419 is a Phase 1 study of Neoplasm that has completed, run by Eli Lilly and Company. The registered enrollment target is 10 participants, below the 201-participant average among 11 other Neoplasm trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02304419, a Phase 1 study of Neoplasm, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up.
Conditions Studied
Interventions
- DRUG Galunisertib
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
What the finished NCT02304419 record still lists
NCT02304419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 201-participant average among 11 other Neoplasm trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Galunisertib is the first listed.
NCT02304419 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02304419 about?
NCT02304419 is a clinical study titled "A Study of Galunisertib on the Immune System in Participants With Cancer". The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up.
What is the current status of trial NCT02304419?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-05. Estimated completion is 2016-08.
What conditions does trial NCT02304419 study?
This clinical trial studies the following conditions: Neoplasm.
What interventions are being tested in trial NCT02304419?
The interventions under investigation include: Galunisertib (DRUG).
Who is sponsoring clinical trial NCT02304419?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02304419 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02304419's enrollment target sits among peer trials
10 12th of 11 the lowest of 11 other Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study of LY2835219 in Participants With Cancer
COMPLETED · Phase 1
-
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
COMPLETED · Phase 1
-
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
COMPLETED · Phase 1
-
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia